Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models-Reference-Cited by-同舟云学术

Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models

Published:2022-02-07 Issue:5 Volume:355 Page:2100467
ISSN:0365-6233
Container-title:Archiv der Pharmazie
language:en
Short-container-title:Archiv der Pharmazie

Author:

Gockel Lukas M.¹^ORCID,Pfeifer Vladlena¹,Baltes Fabian¹,Bachmaier Rafael D.²,Wagner Karl G.²,Bendas Gerd¹,Gütschow Michael³^ORCID,Sosič Izidor⁴,Steinebach Christian³^ORCID

Affiliation:

1. Department of Pharmaceutical & Cell Biological Chemistry Pharmaceutical Institute Bonn Germany

2. Department of Pharmaceutical Technology Pharmaceutical Institute Bonn Germany

3. Department of Pharmaceutical & Medicinal Chemistry Pharmaceutical Institute Bonn Germany

4. Department of Medicinal Chemistry, Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia

Funder

Javna Agencija za Raziskovalno Dejavnost RS

Publisher

Wiley

Subject

Drug Discovery,Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ardp.202100467

Reference51 articles.

1. The transcriptional programme of the androgen receptor (AR) in prostate cancer

2. Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer

3. Androgen Receptor in Prostate Cancer

4. Non-castrate Metastatic Prostate Cancer: Have the Treatment Options Changed?

5. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications;European Journal of Medicinal Chemistry;2024-09

2. Application and challenges of nitrogen heterocycles in PROTAC linker;European Journal of Medicinal Chemistry;2024-07

3. Characteristic roadmap of linker governs the rational design of PROTACs;Acta Pharmaceutica Sinica B;2024-04

4. PROTACs in the Management of Prostate Cancer;PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics;2024

5. Probing Class I Histone Deacetylases (Hdac) with Proteolysis Targeting Chimera (Protac) for the Development of Highly Potent and Selective Degraders;2024